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Abstract
Background: Behcet's disease (BD) is a chronic relapsing multisystem inflammatory disorder with
mucocutaneous, ocular, articular, vascular, gastrointestinal and central nervous system
manifestations. Tumor necrosis factor (TNF)-alpha is believed to play a pivotal role in BD.
Therapeutic blockade of the activity of TNF has been successfully given in a short course of therapy
with favorable effects in patients with BD refractory to conventional immunosuppressive drugs.
We aimed to find out whether a 12-month treatment with infliximab, a chimeric monoclonal
antibody to TNF-alpha, had any beneficial effect in reducing relapses of a patient with long-standing
BD refractory to conventional immunosuppressive drugs.
Case presentation: A 54 year-old-woman with a 35-year history of BD with orogenital
ulcerations, arthritis in the right knee and retinal lesions compatible with vasculitis received
infliximab, 5 mg/kg by a two-hour intravenous infusion. Symptoms improved within 24 hours and
eight days later the genital and oral ulcers healed as well as the arthritis in the right knee subsided.
The retinal infiltrates completely resolved within 10 days. The infusions were repeated at weeks 2,
6, 14, 22 and then every 8 weeks. The patient was able to return to her domestic daily life. No
exacerbation of the mucocutaneous ocular or arthritic symptoms occurred during the treatment
period.
Conclusions: Previous studies have suggested that infliximab given in a short course of treatment
is effective in inducing remission of severe mucocutaneous, gastrointestinal and ocular
manifestations of BD. Our patient received a 12-month infliximab treatment showing a favorable
effect on remission of BD manifestations.
The long-term infliximab treatment appears as a new therapeutic option for patients with active 
BD who failed to respond to conventional immunosuppressive agents.
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Behcet's disease (BD) is a chronic relapsing multisystem
inflammatory disorder that causes orogenital ulcerations,
skin lesions, intraocular inflammation (uveitis and retinal
vasculitis) and less commonly arthritic, vascular, gastroin-
testinal and neurologic manifestations [1,2].
The enhanced inflammatory reaction in BD appears to be
mediated by cytokines derived from T helper type I lym-
phocytes, including tumor necrosis factor (TNF)-alpha
[3].
TNF-alpha is produced by monocytes as part of the
inflammatory cascade in BD and concentrations of TNF
and soluble TNF receptors are increased in the serum of
patients with the active disease [4].
It has been demonstrated that the T lymphocytes express-
ing the gammadelta receptor in BD are activated in vivo
and produce increased amounts of TNF-alpha and inter-
feron-gamma compared with healthy controls [5].
TNF-alpha and interleukin-8 might increase the expres-
sion of the CD11b-CD18 constitutively present on the
polymorphonuclear neutrophils membrane and facilitate
their rolling and diapedesis through the vascular endothe-
lial wall [2,6].
Therapeutic blockade of the activity of TNF has been suc-
cessfully employed to treat Crohn's disease and rheuma-
toid arthritis, two other Th-1 mediated disorders [7].
Recently a short-term anti-TNF treatment was given with
favorable effects in patients with BD refractory to conven-
tional immunosuppressive drugs [8–10].
We aimed to find out whether a 12-month treatment with
infliximab, a chimeric monoclonal antibody to TNF-
alpha, had any beneficial effect in reducing relapses of a
patient with long-standing BD.
Case presentation
A 54-year-old woman with a 35-year history of BD was
admitted to our Unit. The patient fulfilled the Interna-
tional Study Group criteria for diagnosis of BD [1]. She
had a history of recurrent genital and oral aphthous
ulcers. Thirty years ago she was diagnosed retinal lesions
compatible with vasculitis which lead a few years later to
a decrease in visual acuity and blindness in the right eye.
On admission she had orogenital ulcerations, and arthri-
tis in the right knee. The ulcers on the buccal mucosa and
tongue were painful with a diameter ranging from 2 to 6
mm. The right knee was swollen with severe functional
limitation. She had retinal infiltrates in the left eye. Previ-
ous treatment with prednisolone, colchicine, azathio-
prine and cyclosporin was ineffective and the symptoms
recurred periodically.
Erythrocyte sedimentation rate (ESR) was 18.5 mm/h and
C-reactive protein (CRP) was markedly elevated (+++).
CRP levels were measured semiquantitatively and graded
negative (-), detectable (+), elevated (++), and markedly
elevated (+++). PPD Mantoux test was negative.
Infliximab (Remicade, Centocor Inc, Malvern, PA, Scher-
ing Plough SpA, Italy), 5 mg/kg, was administered by a
two-hour intravenous infusion.
The patient was observed for 1 hour after stopping infu-
sion and no adverse effects occurred.
An improvement in symptoms was reported within 24
hours after the first infusion. Eight days later the ulcers
healed and the arthritis subsided as well. The retinal infil-
trates completely resolved within 10 days. A detailed oph-
thalmological examination was done before and 1, 2, 4,7,
10, 14, 21, 28 days after the beginning of the treatment;
then every 14 days for three months and every 28 days for
other eight months.
The infusions were repeated at weeks 2, 6, 14, 22 and then
every 8 weeks for 12 months. No other immunosuppres-
sive agent was administered together with infliximab infu-
sions.
After 4 weeks ESR was 15.5 mm/h and CRP elevated (++).
The patient was able to return to her domestic daily life.
No exacerbation of the mucocutaneous ocular or arthritic
symptoms occurred during the treatment period. After 12
months ESR was 7.5 mm/h and CRP detectable (+). Nei-
ther serious infections nor development of autoantibod-
ies against double-stranded DNA were observed.
Previous studies have suggested that BD can be treated
effectively with TNF blocking therapy. Infliximab given in
a short course of treatment has been reported to be effec-
tive in inducing and maintaining remission of BD. Inflix-
imab was successfully administered for treating severe
mucocutaneous [10–12], gastrointestinal [13–15] and
ocular [16–18] manifestations of BD, with a prompt
improvement of long-lasting symptoms which disap-
peared within a few weeks. The efficacy of infliximab after
the failure of etanercept was also reported [19]. Infliximab
is a chimeric monoclonal antibody directed against TNF-
alpha. The antibody binding to soluble TNF-alpha is
responsible of the initial dramatic improvement in symp-
toms after infliximab infusions.Page 2 of 4
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to transmembrane TNF-alpha expressed on the surface of
activated T cells and macrophages, resulting in lysis of
these cells via complement fixation or antibody-depend-
ent cellular toxicity [20].
Conclusions
It is well known that conventional therapy for BD relies
on available anti-inflammatory and immunomodulatory
agents, and in view of the scarcity of controlled clinical tri-
als, it is to a large extent empirical [8].
Several case series and single reports have suggested that
infliximab given in a short course of treatment is effective
in inducing remission of the various manifestations of BD
[9–18]. Our patient received a 12-month treatment with a
good therapeutic response.
When given in a long-term use infliximab seems to be a
useful therapeutic approach for preventing relapses in
patients with this disease. In particular the long-term inf-
liximab treatment appears a promising new option for
patients with active BD who failed to respond to conven-
tional immunosuppressive agents.
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